Cadence Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Cadence Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-16,080	Closed	-$531K	–	641
2015 Q4	$531K	Buy	+16,080	New	+$524K	0.04%	463
2015 Q3	–	Sell	-26,755	Closed	-$1.2M	–	609
2015 Q2	$1.2M	Buy	26,755 +10,804	+68%	+$420K	0.07%	369
2015 Q1	$488K	Sell	15,951 -49,240	-76%	-$1.92M	0.03%	508
2014 Q4	$3.31M	Sell	65,191 -8,162	-11%	-$365K	0.19%	146
2014 Q3	$2.9M	Sell	73,353 -59,620	-45%	-$2.38M	0.15%	179
2014 Q2	$5.73M	Sell	132,973 -29,127	-18%	-$1.11M	0.27%	115
2014 Q1	$6.48M	Buy	+162,100	New	+$5.89M	0.27%	118

Other funds holding ENTA

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cadence Capital Management's ENTA Position: Q1 2016 in Review

Cadence Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2016, closing a stake of 16,080 shares — an estimated $531K sold.

Cadence Capital Management first reported a position in ENTA in Q1 2014 and held it in 7 quarters. The position peaked at $6.48M in Q1 2014. 152 funds tracked by Wall St. Rank hold ENTA as of Q1 2016.

Cadence Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Cadence Capital Management sold 16,080 Enanta Pharmaceuticals shares in Q1 2016, an estimated $531K.
Cadence Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Cadence Capital Management's Enanta Pharmaceuticals position peaked at $6.48M in Q1 2014.
152 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2016.

Based on Cadence Capital Management's 13F filing for Q1 2016, filed 2 May 2016.